Overview

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Status:
Not yet recruiting
Trial end date:
2024-12-27
Target enrollment:
Participant gender:
Summary
This is a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals